A PHASE 1/2 TRIAL OF THE MEK INHIBITOR MIRDAMETINIB AND TYK2 INHIBITOR DEUCRAVACITINIB FOR ADVANCED MALIGNANT PERIPHERAL NERVE SHEATH TUMORS
$1,361,285FY2024Defense Health AgencyDOD
University Of Alabama At Birmingham, Birmingham AL
University Of Alabama At Birmingham, Birmingham AL